Lloyd James Payne
Directeur/Membre du Conseil chez Cyprotex Discovery Ltd.
Profil
Lloyd James Payne is currently a Director at Cyprotex Discovery Ltd.
He previously worked as a Director at Cyprotex Ltd.
Postes actifs de Lloyd James Payne
| Sociétés | Poste | Début |
|---|---|---|
Cyprotex Discovery Ltd.
 Cyprotex Discovery Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Evotec SE, Cyprotex Discovery Ltd. is a British company that specializes in in vitro toxicology studies using a range of techniques such as cell-based assays, mass spectrometer, fluorescence imaging, and qrt-pcr endpoints. The company is based in Abingdon, UK. The company also offers mitochondrial toxicity assays including seahorse assay, glu/gal assay, mitochondrial biogenesis, mitochondrial membrane potential, and mitochondrial mass. | Directeur/Membre du Conseil | - |
Anciens postes connus de Lloyd James Payne
| Sociétés | Poste | Fin |
|---|---|---|
| CYPROTEX PLC | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Cyprotex Discovery Ltd.
Cyprotex Discovery Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Evotec SE, Cyprotex Discovery Ltd. is a British company that specializes in in vitro toxicology studies using a range of techniques such as cell-based assays, mass spectrometer, fluorescence imaging, and qrt-pcr endpoints. The company is based in Abingdon, UK. The company also offers mitochondrial toxicity assays including seahorse assay, glu/gal assay, mitochondrial biogenesis, mitochondrial membrane potential, and mitochondrial mass. | Commercial Services |
Cyprotex Ltd.
 Cyprotex Ltd. Miscellaneous Commercial ServicesCommercial Services Cyprotex Ltd. provides pharmaceutical research and development services. It offers ADME and pharmacokinetic, Biosciences, in vitro skin and ocular testing, physicochemical profiling, in vitro toxicology, in silico prediction, and endocrine disruption. The company was founded by David Leahy in 1999 and is headquartered in Abingdon, the United Kingdom. | Commercial Services |
